Last reviewed · How we verify
AVX70120 high dose level — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
AVX70120 high dose level (AVX70120 high dose level) — AstriVax Therapeutics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AVX70120 high dose level TARGET | AVX70120 high dose level | AstriVax Therapeutics | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AVX70120 high dose level CI watch — RSS
- AVX70120 high dose level CI watch — Atom
- AVX70120 high dose level CI watch — JSON
- AVX70120 high dose level alone — RSS
Cite this brief
Drug Landscape (2026). AVX70120 high dose level — Competitive Intelligence Brief. https://druglandscape.com/ci/avx70120-high-dose-level. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing